November 2005 Research News
Aromasin Approved for Women with Early-Stage Disease
The Food and Drug Administration (FDA) has approved Aromasin (chemical name: exemestane) to treat post-menopausal women with hormone-receptor-positive, early-stage breast cancer after two to three years of tamoxifen (for a total of five years of hormonal therapy). Read more…
Digital Mammography Better for Younger Women and Women with Dense Breasts
If you've been diagnosed with lobular carcinoma in situ (LCIS), you may have an increased risk of being diagnosed with invasive breast cancer. Read more…
LCIS Associated with Increased Risk of Invasive Breast Cancer
If you're younger than age 50 or have dense breasts, digital mammography may be a good choice for you. Read more…
Updated Guidelines for Treatment After Surgery
If you have early-stage breast cancer and are deciding on treatment after surgery, this article offers one point of view on treatment options. Read more…